rolipram has been researched along with B-Cell Chronic Lymphocytic Leukemia in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Curcumin treatment reduced basal nuclear NF-kappaB levels and 1 microM curcumin augmented both vinca alkaloid and PDE4 inhibitor-induced apoptosis in B-CLL cells." | 2.73 | Preclinical assessment of curcumin as a potential therapy for B-CLL. ( Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M, 2007) |
| "A subset of chronic lymphocytic leukemia (CLL) BCRs interacts with Ags expressed on apoptotic cells, suggesting that CLL BCRs have the potential to internalize apoptotic cell RNA- or DNA-containing fragments with resultant activation of TLR7 or TLR9, respectively." | 1.42 | Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. ( Freeman, BB; Lerner, A; Meyers, JA; Rifkin, IR; Tan, Y; Watkins, AA, 2015) |
| "Rolipram treatment increases levels of transcripts derived from the 1A3 promoter to a greater extent than the 1B promoter." | 1.34 | Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. ( Chaves, J; Lerner, A; Makkinje, A; Meyers, JA; Taverna, J, 2007) |
| "Rolipram/forskolin treatment also induced Bad to accumulate in CLL heavy-membrane fractions, consistent with Bad translocation to mitochondria." | 1.32 | PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. ( Lerner, A; Moon, EY, 2003) |
| "B cell chronic lymphocytic leukemia (B-CLL) is an incurable clonal disease which shows initial responsiveness to a number of chemotherapeutic drugs." | 1.31 | Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. ( Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Medeiros, AS | 1 |
| Wyman, AR | 1 |
| Alaamery, MA | 1 |
| Allain, C | 1 |
| Ivey, FD | 1 |
| Wang, L | 1 |
| Le, H | 1 |
| Morken, JP | 1 |
| Habara, A | 1 |
| Le, C | 1 |
| Cui, S | 1 |
| Lerner, A | 9 |
| Hoffman, CS | 1 |
| Tan, Y | 1 |
| Watkins, AA | 1 |
| Freeman, BB | 1 |
| Meyers, JA | 3 |
| Rifkin, IR | 1 |
| Lindhagen, E | 1 |
| Norberg, M | 1 |
| Kanduri, M | 1 |
| Tobin, G | 1 |
| Säisänen, L | 1 |
| Aberg, M | 1 |
| Gustafsson, MG | 1 |
| Sundström, C | 1 |
| Rosenquist, R | 1 |
| Aleskog, A | 1 |
| Moon, EY | 2 |
| Tiwari, S | 2 |
| Felekkis, K | 1 |
| Flies, A | 1 |
| Sherr, DH | 1 |
| Dong, H | 1 |
| Kim, EJ | 1 |
| Weintraub, L | 2 |
| Epstein, PM | 1 |
| Everett, PC | 1 |
| Makkinje, A | 2 |
| Rabbi, M | 1 |
| Taverna, J | 1 |
| Chaves, J | 1 |
| Kim, DH | 1 |
| Siegmund, B | 1 |
| Welsch, J | 1 |
| Loher, F | 1 |
| Meinhardt, G | 1 |
| Emmerich, B | 1 |
| Endres, S | 1 |
| Eigler, A | 1 |
| Moon, E | 1 |
| Lee, R | 1 |
| Near, R | 1 |
| Wolda, S | 1 |
1 trial available for rolipram and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Preclinical assessment of curcumin as a potential therapy for B-CLL.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2007 |
10 other studies available for rolipram and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases | 2017 |
Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Aged, 80 and over; Apoptosis; Base Sequence; Cell Proli | 2015 |
In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Chromosome Deletion; Ch | 2009 |
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Apoptosis; Caspase 3; Caspase 9; Caspases; Cell Fractionation; | 2003 |
Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Apoptosis; B-Lymphocytes; Benzimidazoles; Colforsin; Cyclic AMP | 2004 |
Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Apoptosis; Cells, Cultured; Colforsin; Cycli | 2005 |
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Apoptosis; Benzamides; Carboxylic Acids; Cyclic | 2007 |
Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antibodies, Anti-Idiotypic; Antigens, CD19; Antineoplastic Agen | 1998 |
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleo | 2001 |
Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Apoptosis; Blotting, Northern; Blotting, Western; Cell Line; Cy | 2002 |